Showing 1821-1830 of 6037 results for "".
- Harrow Partners with Asembia to Create Digital Services and Hub Support for Harrow’s Branded Eye Care Productshttps://modernod.com/news/harrow-partners-with-asembia-to-enhance-provider-and-patient-experience-through-nationwide-digital-services-and-hub-support-for-harrows-branded-eye-care-products/2482530/Harrow announced the nationwide launch of a new digital patient access solution in collaboration with Asembia. This multi-year partnership is designed to expand access to Harrow’s ophthalmic branded products, including Flarex, Ilevro, Maxidex, Maxitrol, Natacyn, Nevanac, Tobradex ST, Verkaz
- Spherix Global Insights Introduces Ophthalmology to Suite of Independent Market Research and Intelligence Serviceshttps://modernod.com/news/spherix-global-insights-introduces-ophthalmology-to-suite-of-independent-market-research-and-intelligence-services/2480450/Spherix Global Insights, a market research firm providing independent coverage of select specialty markets, officially cut the ribbon on their ophthalmology franchise. Spherix derives actionable insights from its frequent, commercially-focused, primary market research, which i
- Alan R. Morse, JD, PhD, Vision and Healthcare Services Innovator, Will Retire As President & CEO of Lighthouse Guildhttps://modernod.com/news/alan-r-morse-jd-phd-vision-and-healthcare-services-innovator-will-retire-as-president-ceo-of-lighthouse-guild/2476695/James M. Dubin, Chairman of the Board of Lighthouse Guild, announced that Alan R. Morse, JD, PhD, will be stepping down later this year as President & CEO of Lighthouse Guild after an extraordinary career of almost 52 years as a leader and innovator in the field
- Ribomic Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-first-injection-in-the-phase-2-clinical-trial-of-rbm-007-tofu-study-in-subjects-with-wet-amd/2477304/Ribomic announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of wet age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States.</
- Zeiss Opens New High-Tech Center in San Francisco Bay Areahttps://modernod.com/news/zeiss-opens-new-high-tech-center-in-san-francisco-bay-area/2479038/Zeiss has completed construction of its new R&D, production, sales and customer service site in the San Francisco Bay Area. Bringing together hundreds of Zeiss employees and key functions under one roof, represents a major milestone in the company’s international innovation and growth
- President-Elect Biden Picks California Attorney General to Lead HHShttps://modernod.com/news/president-elect-biden-picks-california-attorney-general-to-lead-hhs/2478630/President-elect Joe Biden plans to nominate California Attorney General Xavier Becerra to lead the Department of Health and Human Services (HHS), according to
- Oertli Opens New Lean Factory Building in Berneck, Eastern Switzerlandhttps://modernod.com/news/oertli-opens-new-lean-factory-building-in-berneck-eastern-switzerland/2481922/Oertli Instrumente recently celebrated the opening of its new Lean Factory building at its main site in Berneck, Eastern Switzerland. The new Lean Factory covers 11,000 m2 and has the goal of increasing production efficiency and volumes in order to achieve the set growth targets. With a
- Nacuity Pharmaceuticals Advances Phase 1/2 Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progressionhttps://modernod.com/news/nacuity-pharmaceuticals-advances-phase-12-trial-evaluating-npi-002-intravitreal-implant-for-the-delay-of-cataract-progression/2481719/Nacuity Pharmaceuticals announced that a clinical trial site has been added to its phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy.
- FDA Approves New Paragon Contact Lens Manufacturing Facility in Phoenixhttps://modernod.com/news/fda-approves-new-paragon-contact-lens-manufacturing-facility-in-phoenix/2476817/The FDA has approved Paragon Vision Science’s newly-constructed contact lens manufacturing site in suburban Phoenix, paving the way for the company’s ongoing domestic and global expansion. The Gilbert, Ariziona facility will produce advanced ortho-k products such as Paragon CRT for use in
- LensGen Will Present Early Results Of International “Grail” Study At ASCRShttps://modernod.com/news/lensgen-will-present-early-results-of-international-grail-study-at-ascrs/2476515/LensGen will share results from its “Grail” study at the ASCRS annual meeting in San Diego, May 3-7. The results will include the latest available data on patients who have been treated at two international sites.